These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 6117308)

  • 1. Cerebrospinal fluid concentrations of propranolol, pindolol and atenolol in man: evidence for central actions of beta-adrenoceptor antagonists.
    Taylor EA; Jefferson D; Carroll JD; Turner P
    Br J Clin Pharmacol; 1981 Oct; 12(4):549-59. PubMed ID: 6117308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Receptor occupancy in lumbar CSF as a measure of the antagonist activity of atenolol, metoprolol and propranolol in the CNS.
    Kaila T; Marttila R
    Br J Clin Pharmacol; 1993 May; 35(5):507-15. PubMed ID: 8099803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An assessment of the partial agonist activity of Ro 31-1118, flusoxolol and pindolol in man.
    McCaffrey PM; Riddell JG; Shanks RG
    Br J Clin Pharmacol; 1987 Nov; 24(5):571-80. PubMed ID: 2893634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. beta-Adrenoreceptor-blocking agents and the blood-brain barrier.
    Cruickshank JM; Neil-Dwyer G; Cameron MM; McAinsh J
    Clin Sci (Lond); 1980 Dec; 59 Suppl 6():453s-455s. PubMed ID: 7449299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central propranolol and pindolol, but not atenolol nor metoprolol, inhibit sexual behavior in male rats.
    Smith ER; Kacker SR; Raskin A; Yun PT; Davidson JM; Hoffman BB; Clark JT
    Physiol Behav; 1996 Feb; 59(2):241-6. PubMed ID: 8838601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The distribution of propranolol, pindolol and atenolol between human erythrocytes and plasma.
    Taylor EA; Turner P
    Br J Clin Pharmacol; 1981 Oct; 12(4):543-8. PubMed ID: 7295488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ambulatory blood pressure during once-daily randomised double-blind administration of atenolol, metoprolol, pindolol, and slow-release propranolol.
    Floras JS; Jones JV; Hassan MO; Sleight P
    Br Med J (Clin Res Ed); 1982 Nov; 285(6352):1387-92. PubMed ID: 6814568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of beta-adrenoceptor blockade on heart rate and physiological tremor in diabetics with autonomic neuropathy. A comparative study of epanolol, atenolol and pindolol.
    Reid W; Ewing DJ; Harry JD; Smith HJ; Neilson JM; Clarke BF
    Br J Clin Pharmacol; 1987 Apr; 23(4):383-9. PubMed ID: 2883987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term effects of beta blockers atenolol, nadolol, pindolol, and propranolol on lipoprotein metabolism in normolipemic subjects.
    Harvengt C; Heller FR; Martiat P; Van Nieuwenhuyze Y
    J Clin Pharmacol; 1987 Jul; 27(7):475-80. PubMed ID: 2888790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The interaction between H2-receptor antagonists and beta-adrenoceptor blockers.
    Mutschler E; Spahn H; Kirch W
    Br J Clin Pharmacol; 1984; 17 Suppl 1(Suppl 1):51S-57S. PubMed ID: 6146340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intrinsic sympathomimetic activity of (-)-pindolol mediated through a (-)-propranolol-resistant site of the beta1-adrenoceptor in human atrium and recombinant receptors.
    Joseph SS; Lynham JA; Molenaar P; Grace AA; Colledge WH; Kaumann AJ
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Dec; 368(6):496-503. PubMed ID: 14608456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beta-adrenoceptor blockers and the blood-brian barrier.
    Neil-Dwyer G; Bartlett J; McAinsh J; Cruickshank JM
    Br J Clin Pharmacol; 1981 Jun; 11(6):549-53. PubMed ID: 6115665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beta-adrenergic antagonist inhibition of hepatic 3,5,3'-triiodothyronine production.
    Shulkin BL; Peele ME; Utiger RD
    Endocrinology; 1984 Sep; 115(3):858-61. PubMed ID: 6146516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of beta-adrenergic blocking agents on peripheral vascular resistance.
    Rascher W; Mann JF; Schömig A; Dietz R; Lüth JB
    Klin Wochenschr; 1978; 56 Suppl 1():87-90. PubMed ID: 32434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. beta-Adrenoceptor antagonists: new drugs and new indications.
    Koch-Weser J; Frishman WH
    N Engl J Med; 1981 Aug; 305(9):500-6. PubMed ID: 6114433
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of the subacute hemodynamic effects of atenolol, propranolol, pindolol, and nebivolol.
    De Crée J; Cobo C; Geukens H; Verhaegen H
    Angiology; 1990 Feb; 41(2):95-105. PubMed ID: 1968323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of beta-adrenoceptor antagonists in asthmatic patients.
    Ruffin RE; McIntyre EL; Latimer KM; Ward HE; Crockett AJ; Alpers JH
    Br J Clin Pharmacol; 1982; 13(Suppl 2):325S-335S. PubMed ID: 6125185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different changes of plasma membrane beta-adrenoceptors in rat heart after chronic administration of propranolol, atenolol and bevantolol.
    Horinouchi T; Morishima S; Tanaka T; Suzuki F; Tanaka Y; Koike K; Miwa S; Muramatsu I
    Life Sci; 2007 Jul; 81(5):399-404. PubMed ID: 17628611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. beta-blockade, atrial natriuretic peptide and exercise.
    Kantola I; Tarssanen L; Scheinin M; Ruskoaho H; Viinamäki O; Kaila T
    Int J Clin Pharmacol Ther; 1996 Jan; 34(1):12-6. PubMed ID: 8688991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative analysis of beta-1 adrenoceptor agonist and antagonist potency and selectivity of cicloprolol, xamoterol and pindolol.
    Hicks PE; Cavero I; Manoury P; Lefevre-Borg F; Langer SZ
    J Pharmacol Exp Ther; 1987 Sep; 242(3):1025-34. PubMed ID: 2888869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.